Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Aug 14, 2025-

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks and demonstrating a favorable safety and tolerability profile across all dose…